Biosyent (RX) Announces Quarterly Earnings Results

Biosyent (CVE:RX) released its quarterly earnings data on Wednesday. The company reported C$0.09 earnings per share for the quarter, missing analysts’ consensus estimates of C$0.12 by C($0.03), Morningstar.com reports. The firm had revenue of C$5.26 million during the quarter, compared to analysts’ expectations of C$6.48 million.

CVE:RX opened at C$7.15 on Friday. Biosyent has a 12 month low of C$6.93 and a 12 month high of C$10.50.

Separately, Raymond James dropped their price objective on Biosyent from C$12.50 to C$11.00 and set an “outperform” rating for the company in a research note on Thursday.

In related news, insider Rene Christopher Goehrum sold 36,000 shares of the business’s stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of C$9.60, for a total value of C$345,600.00. Also, insider Alfred D’souza sold 14,000 shares of the business’s stock in a transaction dated Friday, November 2nd. The stock was sold at an average price of C$9.34, for a total value of C$130,760.00. Insiders sold 160,263 shares of company stock worth $1,516,325 over the last quarter.

COPYRIGHT VIOLATION WARNING: This piece of content was published by WKRB News and is owned by of WKRB News. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.wkrb13.com/2018/11/23/biosyent-rx-announces-quarterly-earnings-results.html.

Biosyent Company Profile

BioSyent Inc, a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository designed to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of non-muscle invasive papillary bladder cancer.

Read More: Asset Allocation and Your Retirement

Earnings History for Biosyent (CVE:RX)

Receive News & Ratings for Biosyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply